Version:

02-04-2014 01-01-2018: Changes in Adult vaccination 04-11-2021: Updated recommendations for COVID-19 Vaccine 01-01-2023: 2023 vaccination calendar

Footnotes:

1. https://emvolio.gov.gr/
2. PPSV23 recommended from 2 years of age in at-risk groups
3. MenACWY is recommended to all adolescents aged 11-12 years. It is also recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 6 months of age are recommended 3 doses at ages 2, 4 and 12 months (MenACWY-TT vaccine); Infants starting vaccination between 7 and 24 months: 2 doses, 2nd dose to is administered at least 12 weeks after the first dose (MenACWY-TT vaccine); Children starting vaccination after 2 years of age: 2 doses with 8 weeks interval (MenACWY-CRM or MenACWY-TT vaccine); In children who remain at high risk, a booster dose is recommended 3-5 years after completion of their primary course. The MenB vaccine is recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 5 months of age are recommended 4 doses at ages 2, 4, 6 and 12–15 months (MenB-4C); Infants and toddlers starting vaccination at 6 to 23 months of age: 2 doses with minimum 8 weeks interval and a booster dose at age 12–23 months (MenB-4C); Children starting vaccination at 2 to 10 years of age: 2 doses with minimum 8 weeks interval (MenB-4C); Children starting vaccination from the age of 11 years: 2 doses with minimum interval of 1 month (MenB-4C); Individuals aged 10 years and above can be vaccinated with MenB-fHbp with a 3-dose regimen at 0, 1–2, 6 months. More details available at: http://www.infovac.gr/wp-content/uploads/2019/06/%CE%95%CE%98%CE%9D%CE%99%CE%9A%CE%9F-%CE%A0%CE%A1%CE%9F%CE%93%CE%A1%CE%91%CE%9C%CE%9C%CE%91-%CE%95%CE%9C%CE%92%CE%9F%CE%9B%CE%99%CE%91%CE%A3%CE%9C%CE%A9%CE%9D-%CE%A0%CE%91%CE%94%CE%99%CE%A9%CE%9D-%CE%95%CE%A6%CE%97%CE%92%CE%A9%CE%9D-2019.pdf
4. 21 Sept. 2017: temporary recommendation for measles vaccination in Greece. First Dose at 12 months of age, Second dose 3 months later or 4 weeks after Dose 1 in specific groups
5. for detailled information refer to https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/alles-systaseis-ths-ethnikhs-epitrophs-emboliasmwn/11437-skeptiko-emboliasmoy-gia-ton-erphta-zwsthra-aprilios-2023
6. Td booster every 10 years. One of the booster dose should be with Tdacp or Tdacp-IPV
7. Td booster every 10 years. One of the booster dose should be with Tdacp or Tdacp-IPV. A single dose of Tdacp or Tdacp-IPV vaccine should be administered in each pregnancy, preferably from 27 to 36 weeks of gestation, as well as to unvaccinated women who have recently given birth, regardless of the interval between previous Tdacp vaccination.
8. Three doses
9. For individuals born after 1970 (one or two doses depending on vaccination history and clinical history)
10. Two doses recommended to people belonging to specific occupational categories , please refer to official recommendations. Women found to be seronegative during pregnancy should be vaccinated with 2 doses in the postpartum period.
11. Catch-up vaccination up to 18 years for those who missed out on vaccination (HPV vaccine is fully reimbursed in boys and girls aged 15-18 until 31.12.2025). 2 doses scheme up to 18 years. for specific at-risk groups vaccination can be extended up to 26 years.
12. 2 doses (RZV vaccine) in immunocompromised with 2 or more episodes of herpes-zoster
13. ZVL for 60-75 years, RZV for immunocompromised
14. Two doses

More information available at:
https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/


Last update : 21 January 2025